The Dr. Makis Cancer Protocol Manual

This is presented as an exploration of emerging and controversial ideas surrounding drug repurposing in the context of cancer care. It focuses on two compounds that have attracted significant public attention in alternative and experimental health discussions: ivermectin, a widely used antiparasitic medication in human medicine, and fenbendazole, a veterinary antiparasitic agent that has gained interest through anecdotal reports and preliminary laboratory observations. This manual aims to organize available information, reported usage patterns, and theoretical frameworks into a structured format for educational review, while also highlighting the current limits of scientific validation.

Cancer is not a single disease but a broad category of conditions characterized by uncontrolled and abnormal cell growth driven by genetic mutations, environmental influences, and complex biological interactions. Modern oncology relies on evidence-based treatments that have undergone extensive clinical trials, including surgery, chemotherapy, radiation therapy, immunotherapy, and targeted molecular therapies. These approaches are continuously evaluated for safety and effectiveness through regulated scientific processes. In contrast, repurposed drug protocols such as those involving ivermectin and fenbendazole remain outside established oncology guidelines and are not recognized as standard cancer treatments by major medical organizations.

The interest in repurposing existing medications for cancer research stems from a broader scientific strategy known as drug repositioning, where approved drugs are investigated for new therapeutic applications. Ivermectin has been studied in laboratory settings for potential effects on cellular pathways, including inflammation, tumor signaling, and immune modulation. However, most of these findings are preclinical in nature, meaning they are derived from cell cultures or animal models rather than large-scale human clinical trials. Fenbendazole has similarly been examined in limited experimental contexts, with some studies exploring its interaction with microtubule formation in cells, though robust clinical evidence supporting its use in human oncology remains lacking.

The “Dr. Makis Protocol” concept, as referenced in online discussions, is not an officially recognized or standardized medical protocol within oncology practice. Instead, it represents a collection of ideas circulating in public and alternative health spaces, where individuals explore potential off-label or experimental uses of existing medications. These discussions often combine scientific literature, anecdotal experiences, and theoretical interpretations, but they do not constitute validated clinical guidelines.

This manual organizes these ideas into a structured format to help readers understand how such protocols are described, how dosing concepts are discussed in informal settings, and how theoretical combinations are proposed. It also emphasizes the importance of distinguishing between hypothesis-driven exploration and clinically proven medical practice. Any discussion of dosing, protocols, or combined usage in this context should be understood as informational rather than prescriptive, as safety, efficacy, and appropriate medical supervision are essential considerations in any therapeutic intervention.

A significant portion of this guide is dedicated to evaluating the scientific foundations and available evidence behind these compounds, as well as examining the risks, uncertainties, and regulatory limitations associated with their use. It also addresses ethical and legal considerations, particularly in relation to patient safety, informed consent, and adherence to approved medical standards.